Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Operating Results by Reportable Segment (Detail)

v3.7.0.1
Segment Information - Operating Results by Reportable Segment (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Segment Reporting Information [Line Items]      
Net Revenue $ 44,682    
Direct cost of goods (469)    
Sales and marketing costs (2,267)    
Research and development (8,404)    
General and administrative (7,985)    
National Expenses 62,259 $ 15,751  
Segment loss from operations (17,577) $ (15,091)  
Segment assets 211,911   $ 170,731
Dermatology Products Sales [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 2,085    
Direct cost of goods (469)    
Sales and marketing costs (2,267)    
Research and development 0    
General and administrative (319)    
National Expenses 0    
Segment loss from operations (970)    
Segment assets 4,039    
Pharmaceutical And Biotechnology Product Development [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 693    
Direct cost of goods 0    
Sales and marketing costs 0    
Research and development (8,404)    
General and administrative (7,666)    
National Expenses 0    
Segment loss from operations (15,377)    
Segment assets 159,175    
National [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 41,904    
Direct cost of goods 0    
Sales and marketing costs 0    
Research and development 0    
General and administrative 0    
National Expenses (43,134)    
Segment loss from operations (1,230)    
Segment assets $ 48,697